Interstate commerce continues to be at the forefront of the industry's collective mind as we look for solutions to incongruence of supply and demand, stalled equity programs, and fierce competition between and among both licensed participants and illicit businesses.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
This session will look at how an international supply chain for recreational cannabis products can be designed and how the enormous demand for products from legal markets can be satisfied. What conditions need to be created at the level of international law to make global trade possible? And what about import duties, safety standards and Intellectual Property?
We’ll cover where the power to regulate/enforce gets vested, and through which agency/agencies, how cannabis becomes legalized: whether through legislation, ballot measures, or litigation, and the COVID Impact: what an “essential” designation means for cannabis as a driver of international economic development.